home / stock / argnf / argnf news


ARGNF News and Press, Argen X NV From 05/09/22

Stock Information

Company Name: Argen X NV
Stock Symbol: ARGNF
Market: OTC
Website: argenx.com

Menu

ARGNF ARGNF Quote ARGNF Short ARGNF News ARGNF Articles ARGNF Message Board
Get ARGNF Alerts

News, Short Squeeze, Breakout and More Instantly...

ARGNF - argenx SE 2022 Q1 - Results - Earnings Call Presentation

The following slide deck was published by argenx SE in conjunction with their 2022 Q1 earnings call. For further details see: argenx SE 2022 Q1 - Results - Earnings Call Presentation

ARGNF - Tracking Baker Brothers Portfolio - Q4 2021 Update

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

ARGNF - argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2021 Results - Earnings Call Transcript

argenx SE (ARGX) Q4 2021 Earnings Conference Call March 03, 2022 08:30 AM ET Company Participants Beth DelGiacco - Vice President, Investor Relations and Corporate Communications Tim Van Hauwermeiren - Chief Executive Officer Keith Woods - Chief Operating Officer Karl Gubitz - Chief Financial...

ARGNF - argenx SE 2021 Q4 - Results - Earnings Call Presentation

The following slide deck was published by argenx SE in conjunction with their 2021 Q4 earnings call. For further details see: argenx SE 2021 Q4 - Results - Earnings Call Presentation

ARGNF - Immunovant: Speculative Biotech With Proven Class Of Drugs Targeting FcRn Pathway

Plans to initiate phase 3 study using batoclimab for the treatment of patients with myasthenia gravis expected 1st half of 2022. Two additional indications in the pipeline will be announced in August of 2022. Goal to choose two additional indications with the use of batoclimab to ...

ARGNF - argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q3 2021 Results - Earnings Call Transcript

argenx SE (ARGX) Q3 2021 Results Conference Call October 28, 2021 08:30 AM ET Company Participants Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Keith Woods - COO Conference Call Participants Akash Tewari - Jefferies James Gordon - JP Morgan Danielle Brill - Raymond James Yatin Suneja - Guggen...

ARGNF - argenx SE 2021 Q3 - Results - Earnings Call Presentation

The following slide deck was published by argenx SE in conjunction with their 2021 Q3 earnings call. For further details see: argenx SE 2021 Q3 - Results - Earnings Call Presentation

ARGNF - Tracking Baker Brothers Portfolio - Q2 2021 Update

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

ARGNF - Tracking Lone Pine Capital Portfolio - Q2 2021 Update

Lone Pine Capital’s 13F portfolio value increased from $27.53B to $31.66B. The number of positions decreased from 38 to 36. They added Moderna, RH, and Twitter and increased Square and ServiceNow. Also, they dropped Mercadolibre, Netflix, Atlassian, Bilibili, and Snowflake. ...

ARGNF - argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2021 Results - Earnings Call Transcript

argenx SE (ARGX) Q2 2021 Earnings Conference Call July 29, 2021, 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Keith Woods - Chief Operating Officer Conference Call Parti...

Previous 10 Next 10